Trial reportBlood2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
Open access · bronzeAbstract readClinical Trial, Phase IILetterMulticenter Study
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 83 citations in OpenAlex.
- Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.Transfusion · 2025Trial
- Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Unexpected impact on immunohematological diagnostics from transplantation of autologous stem cell preparations containing daratumumab.Haematologica · 2026Article
- Use of Microbial Microarrays to Define Antibody Specificity.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Therapeutic biologics interference in serological and pre-transfusion testing.Frontiers in immunology · 2026Review
- Acute Incompatible Red Blood Cell Transfusion in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Babesiosis and Malaria in the United States: Epidemiology, Research Funding, Medical Progress, & Recommendations for Improvement.Epidemiologia (Basel, Switzerland) · 2025Article
- Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center.Journal of clinical medicine · 2025Article
- Optimal control of multiple myeloma assuming drug resistance and off-target effects.PLoS computational biology · 2025Article
- Article
- A spleen is required for antibody mediated immune enhancement but not for RBC clearance or antigen-modulation in mice.Transfusion · 2025Article
- CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion.Frontiers in immunology · 2025Article
- A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Post-transfusion biotin-labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance.Transfusion · 2024Article
- Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice.The Journal of clinical investigation · 2024Article
- Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression.Blood · 2023Article
- Article
- Whole microbe arrays accurately predict interactions and overall antimicrobial activity of galectin-8 toward distinct strains of Streptococcus pneumoniae.Scientific reports · 2023Article
- The Development and Consequences of Red Blood Cell Alloimmunization.Annual review of pathology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Harold C SullivanCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Christian Gerner-SmidtCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Ajay K NookaDepartment of Hematology and Medical Oncology, and.
Connie M ArthurCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Louisa ThompsonCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Amanda MenerCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Seema R PatelCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Marianne YeeDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA; and.
Ross M FasanoCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Cassandra D JosephsonCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Richard M KaufmanDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
John D RobackCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Sagar LonialDepartment of Hematology and Medical Oncology, and.
Sean R StowellCenter for Transfusion Medicine and Cellular Therapies, Department of Pathology and Laboratory Medicine.
Institute for Transfusion Medicine · USEmory University · USHarvard University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3MExamination of Initiating Factors that Regulate Red Blood Cell AlloimmunizationR01HL135575 · NHLBI · EMORY UNIVERSITY · PI Sean R Stowell · 2017 to 2026
$2.8MTraining Grant in Transfusion Medicine (T32)T32HL069769 · NHLBI · EMORY UNIVERSITY · PI Una T O'Doherty, John D Roback · 2004 to 2026
$2.6MExamination of Innate Immunity Against Molecular MimicryDP5OD019892 · OD · EMORY UNIVERSITY · PI STOWELL, SEAN R · 2014 to 2018
$2.2MNHLBI NIH HHS R01 HL135575NHLBI NIH HHS T32 HL069769NIGMS NIH HHS T32 GM008169NIH HHS DP5 OD019892
Abstract
PubMed holds no abstract for this paper.
Indexed as
ErythrocytesMultiple MyelomaADP-ribosyl Cyclase 1Antibodies, MonoclonalFemaleHumansMaleMembrane GlycoproteinsADP-ribosyl Cyclase 1Antibodies, MonoclonalCD38 protein, humandaratumumabMembrane Glycoproteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.